TRUSTECH
SESAMES Awards, focusing on innovation
Each year at TRUSTECH, the SESAMES Awards are given to the best innovations in the fields of payments, identification, digital security and wireless technologies.
18 exhibiting companies have been selected as finalists by a jury made up of 18 international experts. The selection was based on three fundamental criteria: the innovative characteristics of the product/service submitted, the market suitability and the strength of the pitch.
It's on the Main Stage of TRUSTECH that the 6 SESAMES winners will be rewarded on 29 November in the categories of e-transaction, retail and manufacturing; then on 30 November in the categories of IoT, e-government and cyber security.
The 18 finalists of the SESAMES awards
|
Company |
Name of project |
Category |
||
| AUVERCLOUD SAS (FR) | Cybersecurity | |||
| BioSSL ltd (UK) | ||||
| Spire Payments (UK) | ||||
| FEITIAN TECHNOLOGIES CO., LTD (CN) | eGovernment | |||
| Vision Box (PO) | ||||
| IMPRIMERIE NATIONALE/SPS (FR) | ||||
| MeReal Biometrics (HK) | eTransactions | |||
|
SCOPECARD, a digital solution for humanitarian food assistance |
||||
| TableSafe (USA) | ||||
| KEOLABS (FR) | IoT | |||
| RFID / NFC Anti-Counterfeit Solution | ||||
| SMARTRAC TECHNOLOGY GROUP (NL) | ||||
| COMPRION GmbH (DEU) |
Manufacturing and
|
|||
| COMPRION GmbH (DEU) | ||||
| SPS (FR) | ||||
| VirtuCrypt (USA) | Retail | |||
| TableSafe (USA) | ||||
|
TAS Group (IT) |
EasySelf |
Major players and start-ups brought together by innovation
The Main Stage of TRUSTECH will also be dedicated to the 40 start-ups
in
the Fintech, IoT, payments and digital identity sectors, invited to
participate in the pitch sessions.
The exhibitors and sponsors
will also present their latest products and services on the Main Stage.
Focus on a few highlights
Connected objects
Wetech
has developed a range of connected accessories and jewellery (watches,
bracelets, rings, necklaces, etc.), using wireless technology to be used
as POS. The company has also created apps paired to their wearables, in
order to control and secure them.
Payments
Companies such as TAS
Group
is helping to bring down barriers which exist in the field of
cross-border payments by simplifying the validation and processing of
this type of operation by taking into account the local regulations and
commercial practices. As for Snapswap
,
the company combines mobile messenger app functions (such as Facebook
Messenger and WhatsApp) with digital wallet and peer-to-peer
transactions (such as PayPal) into a single app called Gloneta
.
Biometrics
Another field where innovation is
particularly impressive is biometrics; companies such as Flexenable
and
Innovatrics
both integrate digital fingerprint readers on smart
cards in order to increase security and broaden their functionalities.
Point of sale terminals
The main stakeholders on this
market, such as Spire Payments, XAC Automation and Verifone with " Carbon
"
will present the latest generation of point of sale terminals. These
latest products now include advanced functionalities, access to the
cloud and the availability of various apps.
More information and registration at www.trustech-event.com
About TRUSTECH (Incorporating Cartes): Created over 30 years ago under the name CARTES SECURE CONNEXIONS to promote the new-born technology of smart cards, it has been re-named TRUSTECH (incorporating CARTES), to better reflect the way the industry and the event have evolved, and its focus on trust-based technologies.
About COMEXPOSIUM: The COMEXPOSIUM Group, one of the world’s leading event organizers, is involved in more than 170 B2C and B2B events across 11 different sectors, including food, agriculture, fashion, security, digital technologies, construction, high tech, optics and transport. COMEXPOSIUM hosts more than 3 million visitors and 45,000 exhibitors in 26 countries around the world. COMEXPOSIUM operates globally with a presence in over 30 countries.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161123005542/en/
Contact:
TRUSTECH
Press contact: Vianova agency
Sandra
Codognotto, 01 53 32 28 58
codognotto@vianova-rp.com
or
Lisa
Dubreuil, 01 53 32 28 37
corporate@vianova-rp.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom